title: Improvement of sinus disease in cystic fibrosis with ivacaftor therapy.
authors.affiliation: Department of Pediatrics, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, Ohio.
authors.forename: Don
authors.initials: D
authors.lastname: Hayes
authors.forename: Karen S
authors.initials: KS
authors.lastname: McCoy
authors.forename: Shahid I
authors.initials: SI
authors.lastname: Sheikh
mesh_terms: D000085:Acetates / Q000627:therapeutic use; D000328:Adult; D000627:Aminophenols / Q000627:therapeutic use*; D000730:Androstadienes / Q000627:therapeutic use; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D003521:Cyclopropanes; D003550:Cystic Fibrosis / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D000068298:Fluticasone; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D010254:Paranasal Sinus Diseases / Q000150:complications* / Q000188:drug therapy*; D011804:Quinolines / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000150:complications / Q000188:drug therapy; D013440:Sulfides; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000085:Acetates; D000627:Aminophenols; D000730:Androstadienes; D018926:Anti-Allergic Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D015363:Quinolones; D013440:Sulfides; C545203:ivacaftor; D000068298:Fluticasone; C093875:montelukast